Patients

Being treated in a Comprehensive Cancer Center

Find out more about us

Healthcare professionals

Unicancer care and research

Your page

Find a Center

Retrouvez les Centres de lutte contre le cancer sur l'ensemble du territoire

La recherche

Unicancer research

Find out more

27/05/2020

The Unicancer network at the ASCO20 congress

The scientific and medical teams of Unicancer, the only French hospital network entirely devoted to fighting cancer, will present their research results at the 56th edition of the congress of the American Society of Clinical Oncology (ASCO) from May 29 to 31, 2020, which this year will take place virtually due to the COVID-19 pandemic.

 

The achievements of the R&D of Unicancer presented at ASCO 2020

Research in the French Comprehensive Cancer Centers presented at ASCO 2020

Video on the PADA-1 study from UCBG Unicancer Expert Group

 

Unicancer is an academic sponsor and operator of clinical trials in cancer research. Its Research & Development department closely works with the clinical research units of the French Comprehensive Cancer Centers (FCCC) and other healthcare centers, in France and abroad.

The R&D of Unicancer is at the forefront of oncology research and places innovation at the heart of its mission. Its activity revolves around three main themes: clinical research, translational research and real-life medical data.

 

Key figures :

FCCCs and the R&D of Unicancer:

Production of 1/3 of French oncology publications at the international level

More than 600 active clinical trials promoted

More than 15% of patients treated in FCCC are included in a clinical trial (compared to 8.5% on average in French healthcare centers)

The R&D of Unicancer:

1st academic sponsor of oncology clinical trials in Europe

Approximately 6 500 patients included and more than 55 000 patients registered in the ESMÉ database

17 research groups, internationally renowned, including 6 labeled by INCa

90 active clinical trials promoted by the Unicancer R&D department

 

 

 

 

 

 

 

The achievements of the R&D of Unicancer presented at ASCO 2020

 

Oral presentations

PRODIGE 23 study

« Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in patients with locally advanced rectal cancer: Final results of PRODIGE 23 phase III trial, a UNICANCER GI trial. »

Présentateur : Pr. T. Conroy, Institut de Cancérologie de Lorraine, Nancy

Coordinateur de l’étude PRODIGE 23

Abstract # : 4007

 

Promoted by Unicancer, the PRODIGE 23 study validates a strategy of primary chemotherapy with neoadjuvant mFOLFIRINOX before preoperative chemoradiation in patients with a recent diagnosis of locally advanced rectal cancer (stages II or III), with an improvement in survival without relapse by 31%.

Unicancer Gastro-intestinal Group (UCGI) : This cooperative group brings together multidisciplinary French experts (oncologists, radiotherapists, surgeons, etc.) developing clinical trials in the gastrointestinal field.

More infos

 

PADA-1 study

« Prognostic impact of ESR1 mutations in ER+ HER2- MBC patients prior treated with first line AI and palbociclib: An exploratory analysis of the PADA-1 trial. »

Présentateur : Pr. F. C. Bidard, Institut Curie, Centre René Huguenin, Saint Cloud, France

Coordinateur de l’étude PADA-1

Abstract # : 1010

 

Promoted by Unicancer, the PADA-1 study aims to demonstrate the clinical utility of detecting and monitoring ESR1 gene mutations from liquid biopsies. This study is conducted on patients with metastatic breast cancer treated with first line palbociclib-AI combination.

The objective of this group is to promote and develop innovative clinical trials improving the care of patients with breast cancer.

More infos

 

Posters

 

Reaserch in the French Comprehensive Cancer Centers presented at the ASCO 2020

Non-exhaustive list - Please look on the website of each center for more information

 

Oral Presentations

 

FCCC : Gustave Roussy, Villejuif 

Clinical Science Symposium

Pooled ctDNA analysis of the MONALEESA (ML) phase III advanced breast cancer (ABC) trials.

Abstract # : 1009

 

FCCC : Institut Curie, Paris | Gustave Roussy, Villejuif

Oral Abstract Session

 

 

 

FCCC : Institut Claudius Regaud, Toulouse

Clinical Science Symposium

 

 

FCCC : Institut Claudius Regaud, Toulouse

Clinical Science Symposium

 

 

 

Posters 

FCCC : Centre Oscar Lambret, Lille

Poster Session

 
 

FCCC : Institut de Cancérologie de Lorraine​, Nancy

Publication Only

Targeted PCR vs NGS for molecular diagnostic in solid tumors and liquid biopsies. How to choose in real-life.

Abstract # : e15576

 

FCCC : Institut de Cancérologie de Lorraine, Nancy

Publication Only

Muscle impairment during follow-up as an independent prognostic factor for poor overall survival in pancreatic cancer.

Abstract # : e16726

 

 

 

 

Video on the PADA-1 study from UCBG Unicancer Expert Group

 

Breast cancer - The PADA-1 Study

Presenter: Dr Thomas Bachelot, Centre Léon Bérard, Lyon

President du Groupe French Breast Cancer Intergroup - Unicancer (UCBG)

Download the presentation